Case studies
Financial statements
Our long-standing collaborations with pharmaceutical leaders exemplify our commitment to scientific rigor, operational excellence, and shared success. Through dedicated centers, we deliver integrated solutions that accelerate innovation, support complex programs, and build enduring value for our customers.
Since 2007, when we launched our first dedicated research center, we have pioneered a unique model of long-term partnerships. Throughout FY25, we operated dedicated centers for three global pharmaceutical leaders – Amgen, Baxter, and Bristol Myers Squibb. Each center reflects a deep, evolving collaboration that supports diverse scientific objectives.
Our centers are designed to function as seamless extensions of our partners’ internal R&D teams, equipped with ring-fenced infrastructure and staffed by an exclusive team of multidisciplinary scientists and support personnel. These facilities uphold the highest regulatory standards while also mirroring the working norms of our partners.
The enduring success of the dedicated center model is based on a foundation of transparency, scientific excellence, and a flexible operating model. Our ability to scale talent, upgrade technologies, and expand capabilities has helped us meet evolving customer needs and deliver sustained value over time.
With over 27 years of collaboration, our partnership with Bristol Myers Squibb (BMS) only continues to strengthen. BBRC serves as a highly diversified and productive research and development site for BMS and delivered successfully on a wide range of objectives throughout FY25, while also expanding the scope of the collaboration to include global IT support.
Syngene scientists within the center are led by a team of BMS leaders based in Bengaluru and collaborate closely with scientists at other BMS locations. This enduring partnership was underscored during FY25 by multiple visits from senior BMS leaders. Their presence highlighted the continued trust and collaboration that defines our long-standing relationship.
In the fourth quarter of FY25, BBRC hosted its biannual “Science Fest”, a celebration of innovation and collaboration. The event featured scientific talks, poster presentations, and panel discussions with senior leaders from both BMS and Syngene, concluding with a vibrant cultural showcase by the BBRC team.
SARC, our dedicated center for Amgen, was established in 2016 in Bengaluru, following the start of our partnership in 2012. Since that time, the Syngene scientists within the center have collaborated with scientists at Amgen sites in the U.S., across synthetic and medicinal chemistry (including peptide chemistry), antibody and protein reagents, biological assays, pharmacokinetics and drug metabolism, and pharmaceutical development.
In December 2024, Amgen updated the engagement agreement to better support discovery efforts, restructuring the dedicated center to focus exclusively on pharmaceutical development from April 1, 2025, forward. Therefore, these dedicated facilities will henceforth no longer be referred to as SARC. Both parties remain committed to the success of this ongoing collaboration.
Our long-standing partnership with Baxter advanced significantly this year, marked by a 15% increase in team size and expanded infrastructure. We successfully delivered five complex New Product Development (NPD) projects, including both large and small molecule programs, in support of global regulatory submissions. Our efforts additionally included support for Baxter’s nitrosamine testing program, covering all global business units.
Consistent delivery, technical rigor, and high-quality analytical services earned strong appreciation from Baxter leadership and led to the award of additional integrated product development projects. We also achieved key regulatory milestones, including a successful Health Canada inspection and ISO 17025 (NABL) accreditation, further reinforcing customer confidence.
Throughout FY25, operational efficiency and compliance were strengthened through Lean Six Sigma and digital transformation initiatives. All key performance metrics remained on track, supported by systems designed to streamline workflows and enhance service delivery.
